Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 14 entries
Sorted by: Best Match Show Resources per page
[Research progress on the immune checkpoint inhibitors induced cardiotoxicity].

Zhonghua xin xue guan bing za zhi

Lyu SS, Yang YM.
PMID: 31550849
Zhonghua Xin Xue Guan Bing Za Zhi. 2019 Sep 24;47(9):748-751. doi: 10.3760/cma.j.issn.0253-3758.2019.09.019.

No abstract available.

Cite
Lyu SS, Yang YM. [Research progress on the immune checkpoint inhibitors induced cardiotoxicity]. Zhonghua Xin Xue Guan Bing Za Zhi. 2019;47(9):748-751doi: 10.3760/cma.j.issn.0253-3758.2019.09.019.
Lyu, S. S., & Yang, Y. M. (2019). [Research progress on the immune checkpoint inhibitors induced cardiotoxicity]. Zhonghua xin xue guan bing za zhi, 47(9), 748-751. https://doi.org/10.3760/cma.j.issn.0253-3758.2019.09.019
Lyu, S S, and Yang, Y M. "[Research progress on the immune checkpoint inhibitors induced cardiotoxicity]." Zhonghua xin xue guan bing za zhi vol. 47,9 (2019): 748-751. doi: https://doi.org/10.3760/cma.j.issn.0253-3758.2019.09.019
Lyu SS, Yang YM. [Research progress on the immune checkpoint inhibitors induced cardiotoxicity]. Zhonghua Xin Xue Guan Bing Za Zhi. 2019 Sep 24;47(9):748-751. doi: 10.3760/cma.j.issn.0253-3758.2019.09.019. Chinese. PMID: 31550849.
Copy Download .nbib Format: NLM
Nivolumab and Ipilimumab-induced Acute Inflammatory Demyelinating Polyradiculoneuropathy: A Case Report.

Journal of immunotherapy (Hagerstown, Md. : 1997)

Pomerantz M, Lichtenstein DA, Niesvizky-Kogan I, Sohal R, Leibovitch J, Basnet A.
PMID: 31261166
J Immunother. 2019 Nov/Dec;42(9):348-349. doi: 10.1097/CJI.0000000000000285.

Immunotherapies such as the cytotoxic T-lymphocyte-associated protein 4 inhibitor ipilimumab and the programmed cell death protein 1 inhibitor nivolumab have become ubiquitous in cancer treatment. Recently, the FDA approved nivolumab with or without ipilimumab for the treatment of refractory...

Cite
Pomerantz M, Lichtenstein DA, Niesvizky-Kogan I, et al. Nivolumab and Ipilimumab-induced Acute Inflammatory Demyelinating Polyradiculoneuropathy: A Case Report. J Immunother. 2019;42(9):348-349doi: 10.1097/CJI.0000000000000285.
Pomerantz, M., Lichtenstein, D. A., Niesvizky-Kogan, I., Sohal, R., Leibovitch, J., & Basnet, A. (2019). Nivolumab and Ipilimumab-induced Acute Inflammatory Demyelinating Polyradiculoneuropathy: A Case Report. Journal of immunotherapy (Hagerstown, Md. : 1997), 42(9), 348-349. https://doi.org/10.1097/CJI.0000000000000285
Pomerantz, Madison, et al. "Nivolumab and Ipilimumab-induced Acute Inflammatory Demyelinating Polyradiculoneuropathy: A Case Report." Journal of immunotherapy (Hagerstown, Md. : 1997) vol. 42,9 (2019): 348-349. doi: https://doi.org/10.1097/CJI.0000000000000285
Pomerantz M, Lichtenstein DA, Niesvizky-Kogan I, Sohal R, Leibovitch J, Basnet A. Nivolumab and Ipilimumab-induced Acute Inflammatory Demyelinating Polyradiculoneuropathy: A Case Report. J Immunother. 2019 Nov/Dec;42(9):348-349. doi: 10.1097/CJI.0000000000000285. PMID: 31261166.
Copy Download .nbib Format: NLM
Hyperprogression in Patients With Cancer Receiving Immune Checkpoint Inhibitors.

JAMA network open

Sehgal K.
PMID: 33760084
JAMA Netw Open. 2021 Mar 01;4(3):e211839. doi: 10.1001/jamanetworkopen.2021.1839.

No abstract available.

Cite
Sehgal K. Hyperprogression in Patients With Cancer Receiving Immune Checkpoint Inhibitors. JAMA Netw Open. 2021;4(3):e211839doi: 10.1001/jamanetworkopen.2021.1839.
Sehgal, K. (2021). Hyperprogression in Patients With Cancer Receiving Immune Checkpoint Inhibitors. JAMA network open, 4(3), e211839. https://doi.org/10.1001/jamanetworkopen.2021.1839
Sehgal, Kartik. "Hyperprogression in Patients With Cancer Receiving Immune Checkpoint Inhibitors." JAMA network open vol. 4,3 (2021): e211839. doi: https://doi.org/10.1001/jamanetworkopen.2021.1839
Sehgal K. Hyperprogression in Patients With Cancer Receiving Immune Checkpoint Inhibitors. JAMA Netw Open. 2021 Mar 01;4(3):e211839. doi: 10.1001/jamanetworkopen.2021.1839. PMID: 33760084.
Copy Download .nbib Format: NLM
Neurological Adverse Events Associated with Immune Checkpoint Inhibitors: Diagnosis and Management.

Current neurology and neuroscience reports

Astaras C, de Micheli R, Moura B, Hundsberger T, Hottinger AF.
PMID: 29392441
Curr Neurol Neurosci Rep. 2018 Feb 01;18(1):3. doi: 10.1007/s11910-018-0810-1.

PURPOSE OF REVIEW: Immune checkpoint inhibitors represent a major step forward in the field of oncologic immunotherapy these last years and have significantly increased survival of cancer patients in an ever-growing number of indications. These agents block specific immune...

Cite
Astaras C, de Micheli R, Moura B, et al. Neurological Adverse Events Associated with Immune Checkpoint Inhibitors: Diagnosis and Management. Curr Neurol Neurosci Rep. 2018;18(1):3doi: 10.1007/s11910-018-0810-1.
Astaras, C., de Micheli, R., Moura, B., Hundsberger, T., & Hottinger, A. F. (2018). Neurological Adverse Events Associated with Immune Checkpoint Inhibitors: Diagnosis and Management. Current neurology and neuroscience reports, 18(1), 3. https://doi.org/10.1007/s11910-018-0810-1
Astaras, Christophoros, et al. "Neurological Adverse Events Associated with Immune Checkpoint Inhibitors: Diagnosis and Management." Current neurology and neuroscience reports vol. 18,1 (2018): 3. doi: https://doi.org/10.1007/s11910-018-0810-1
Astaras C, de Micheli R, Moura B, Hundsberger T, Hottinger AF. Neurological Adverse Events Associated with Immune Checkpoint Inhibitors: Diagnosis and Management. Curr Neurol Neurosci Rep. 2018 Feb 01;18(1):3. doi: 10.1007/s11910-018-0810-1. PMID: 29392441.
Copy Download .nbib Format: NLM
[New AMM: Nivolumab for advanced oesophageal squamous cell carcinomia after first line of chemotherapy].

Bulletin du cancer

Reich M, Coutzac C.
PMID: 33531154
Bull Cancer. 2021 Mar;108(3):228-229. doi: 10.1016/j.bulcan.2020.12.005. Epub 2021 Jan 30.

No abstract available.

Cite
Reich M, Coutzac C. Nouvelles AMMs au niveau européen : nivolumab – carcinome épidermoïde de l’œsophage non opérable en deuxième ligne thérapeutique. [New AMM: Nivolumab for advanced oesophageal squamous cell carcinomia after first line of chemotherapy]. Bull Cancer. 2021;108(3):228-229doi: 10.1016/j.bulcan.2020.12.005.
Reich, M., & Coutzac, C. (2021). Nouvelles AMMs au niveau européen : nivolumab – carcinome épidermoïde de l’œsophage non opérable en deuxième ligne thérapeutique. [New AMM: Nivolumab for advanced oesophageal squamous cell carcinomia after first line of chemotherapy]. Bulletin du cancer, 108(3), 228-229. https://doi.org/10.1016/j.bulcan.2020.12.005
Reich, Mathilde, and Coutzac, Clelia. "Nouvelles AMMs au niveau européen : nivolumab – carcinome épidermoïde de l’œsophage non opérable en deuxième ligne thérapeutique." [New AMM: Nivolumab for advanced oesophageal squamous cell carcinomia after first line of chemotherapy]. Bulletin du cancer vol. 108,3 (2021): 228-229. doi: https://doi.org/10.1016/j.bulcan.2020.12.005
Reich M, Coutzac C. Nouvelles AMMs au niveau européen : nivolumab – carcinome épidermoïde de l’œsophage non opérable en deuxième ligne thérapeutique. [New AMM: Nivolumab for advanced oesophageal squamous cell carcinomia after first line of chemotherapy]. Bull Cancer. 2021 Mar;108(3):228-229. doi: 10.1016/j.bulcan.2020.12.005. Epub 2021 Jan 30. French. PMID: 33531154.
Copy Download .nbib Format: NLM
Outcomes and toxicities of immune checkpoint inhibitors in colorectal cancer: a real-world retrospective analysis.

Cancer communications (London, England)

Zhou C, Jiang T, Li R, Yuan Y, Xie W, Huang X, Wang Q, Chang H, Chen G, Li Y, Zeng Z, Xiao W, Gao Y.
PMID: 34327863
Cancer Commun (Lond). 2021 Sep;41(9):921-924. doi: 10.1002/cac2.12199. Epub 2021 Jul 30.

No abstract available.

Cite
Zhou C, Jiang T, Li R, et al. Outcomes and toxicities of immune checkpoint inhibitors in colorectal cancer: a real-world retrospective analysis. Cancer Commun (Lond). 2021;41(9):921-924doi: 10.1002/cac2.12199.
Zhou, C., Jiang, T., Li, R., Yuan, Y., Xie, W., Huang, X., Wang, Q., Chang, H., Chen, G., Li, Y., Zeng, Z., Xiao, W., & Gao, Y. (2021). Outcomes and toxicities of immune checkpoint inhibitors in colorectal cancer: a real-world retrospective analysis. Cancer communications (London, England), 41(9), 921-924. https://doi.org/10.1002/cac2.12199
Zhou, Chengjing, et al. "Outcomes and toxicities of immune checkpoint inhibitors in colorectal cancer: a real-world retrospective analysis." Cancer communications (London, England) vol. 41,9 (2021): 921-924. doi: https://doi.org/10.1002/cac2.12199
Zhou C, Jiang T, Li R, Yuan Y, Xie W, Huang X, Wang Q, Chang H, Chen G, Li Y, Zeng Z, Xiao W, Gao Y. Outcomes and toxicities of immune checkpoint inhibitors in colorectal cancer: a real-world retrospective analysis. Cancer Commun (Lond). 2021 Sep;41(9):921-924. doi: 10.1002/cac2.12199. Epub 2021 Jul 30. PMID: 34327863; PMCID: PMC8441054.
Copy Download .nbib Format: NLM
Immune-Related Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitors.

Current rheumatology reports

Sandigursky S, Mor A.
PMID: 30191417
Curr Rheumatol Rep. 2018 Sep 06;20(10):65. doi: 10.1007/s11926-018-0770-0.

PURPOSE OF REVIEW: With the advent of cancer immunotherapy and immune checkpoint inhibitors, patients with malignancies can now achieve durable remissions for conditions previously described as terminal. However, immune-related adverse events (irAEs) associated with cancer immunotherapy have become an...

Cite
Sandigursky S, Mor A. Immune-Related Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitors. Curr Rheumatol Rep. 2018;20(10):65doi: 10.1007/s11926-018-0770-0.
Sandigursky, S., & Mor, A. (2018). Immune-Related Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitors. Current rheumatology reports, 20(10), 65. https://doi.org/10.1007/s11926-018-0770-0
Sandigursky, Sabina, and Mor, Adam. "Immune-Related Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitors." Current rheumatology reports vol. 20,10 (2018): 65. doi: https://doi.org/10.1007/s11926-018-0770-0
Sandigursky S, Mor A. Immune-Related Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitors. Curr Rheumatol Rep. 2018 Sep 06;20(10):65. doi: 10.1007/s11926-018-0770-0. PMID: 30191417; PMCID: PMC6488223.
Copy Download .nbib Format: NLM
Encephalitis as an immune-related adverse event.

Journal of neurology, neurosurgery, and psychiatry

Suzuki S.
PMID: 32312874
J Neurol Neurosurg Psychiatry. 2020 Jul;91(7):680. doi: 10.1136/jnnp-2020-323212. Epub 2020 Apr 20.

No abstract available.

Cite
Suzuki S. Encephalitis as an immune-related adverse event. J Neurol Neurosurg Psychiatry. 2020;91(7):680doi: 10.1136/jnnp-2020-323212.
Suzuki, S. (2020). Encephalitis as an immune-related adverse event. Journal of neurology, neurosurgery, and psychiatry, 91(7), 680. https://doi.org/10.1136/jnnp-2020-323212
Suzuki, Shigeaki. "Encephalitis as an immune-related adverse event." Journal of neurology, neurosurgery, and psychiatry vol. 91,7 (2020): 680. doi: https://doi.org/10.1136/jnnp-2020-323212
Suzuki S. Encephalitis as an immune-related adverse event. J Neurol Neurosurg Psychiatry. 2020 Jul;91(7):680. doi: 10.1136/jnnp-2020-323212. Epub 2020 Apr 20. PMID: 32312874.
Copy Download .nbib Format: NLM
Immune checkpoint inhibitor associated neurotoxicity: Much more than meets the eye.

Immunology letters

Raibagkar P.
PMID: 32092358
Immunol Lett. 2020 May;221:72-74. doi: 10.1016/j.imlet.2020.02.007. Epub 2020 Feb 21.

No abstract available.

Cite
Raibagkar P. Immune checkpoint inhibitor associated neurotoxicity: Much more than meets the eye. Immunol Lett. 2020;221:72-74doi: 10.1016/j.imlet.2020.02.007.
Raibagkar, P. (2020). Immune checkpoint inhibitor associated neurotoxicity: Much more than meets the eye. Immunology letters, 22172-74. https://doi.org/10.1016/j.imlet.2020.02.007
Raibagkar, Pooja. "Immune checkpoint inhibitor associated neurotoxicity: Much more than meets the eye." Immunology letters vol. 221 (2020): 72-74. doi: https://doi.org/10.1016/j.imlet.2020.02.007
Raibagkar P. Immune checkpoint inhibitor associated neurotoxicity: Much more than meets the eye. Immunol Lett. 2020 May;221:72-74. doi: 10.1016/j.imlet.2020.02.007. Epub 2020 Feb 21. PMID: 32092358.
Copy Download .nbib Format: NLM
Ipilimumab and Nivolumab in Rare Tumors S1609: Neuroendocrine-Letter.

Clinical cancer research : an official journal of the American Association for Cancer Research

Sonbol MB, Halfdanarson TR.
PMID: 32414760
Clin Cancer Res. 2020 May 15;26(10):2433. doi: 10.1158/1078-0432.CCR-20-0443.

No abstract available.

Cite
Sonbol MB, Halfdanarson TR. Ipilimumab and Nivolumab in Rare Tumors S1609: Neuroendocrine-Letter. Clin Cancer Res. 2020;26(10):2433doi: 10.1158/1078-0432.CCR-20-0443.
Sonbol, M. B., & Halfdanarson, T. R. (2020). Ipilimumab and Nivolumab in Rare Tumors S1609: Neuroendocrine-Letter. Clinical cancer research : an official journal of the American Association for Cancer Research, 26(10), 2433. https://doi.org/10.1158/1078-0432.CCR-20-0443
Sonbol, Mohamad B, and Halfdanarson, Thorvardur R. "Ipilimumab and Nivolumab in Rare Tumors S1609: Neuroendocrine-Letter." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 26,10 (2020): 2433. doi: https://doi.org/10.1158/1078-0432.CCR-20-0443
Sonbol MB, Halfdanarson TR. Ipilimumab and Nivolumab in Rare Tumors S1609: Neuroendocrine-Letter. Clin Cancer Res. 2020 May 15;26(10):2433. doi: 10.1158/1078-0432.CCR-20-0443. PMID: 32414760.
Copy Download .nbib Format: NLM
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum.

Annals of neurology

Dubey D, David WS, Reynolds KL, Chute DF, Clement NF, Cohen JV, Lawrence DP, Mooradian MJ, Sullivan RJ, Guidon AC.
PMID: 32086972
Ann Neurol. 2020 May;87(5):659-669. doi: 10.1002/ana.25708. Epub 2020 Mar 10.

Expanding use of immune-checkpoint inhibitors (ICIs) underscores the importance of accurate diagnosis and timely management of neurological immune-related adverse events (irAE-N). We evaluate the real-world frequency, phenotypes, co-occurring immune-related adverse events (irAEs), and long-term outcomes of severe, grade III...

Cite
Dubey D, David WS, Reynolds KL, et al. Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum. Ann Neurol. 2020;87(5):659-669doi: 10.1002/ana.25708.
Dubey, D., David, W. S., Reynolds, K. L., Chute, D. F., Clement, N. F., Cohen, J. V., Lawrence, D. P., Mooradian, M. J., Sullivan, R. J., & Guidon, A. C. (2020). Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum. Annals of neurology, 87(5), 659-669. https://doi.org/10.1002/ana.25708
Dubey, Divyanshu, et al. "Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum." Annals of neurology vol. 87,5 (2020): 659-669. doi: https://doi.org/10.1002/ana.25708
Dubey D, David WS, Reynolds KL, Chute DF, Clement NF, Cohen JV, Lawrence DP, Mooradian MJ, Sullivan RJ, Guidon AC. Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum. Ann Neurol. 2020 May;87(5):659-669. doi: 10.1002/ana.25708. Epub 2020 Mar 10. PMID: 32086972.
Copy Download .nbib Format: NLM
Systemic Vasculitis Associated With Immune Check Point Inhibition: Analysis and Review.

Current rheumatology reports

Crout TM, Lennep DS, Kishore S, Majithia V.
PMID: 31115712
Curr Rheumatol Rep. 2019 May 21;21(6):28. doi: 10.1007/s11926-019-0828-7.

PURPOSE OF REVIEW: Immunotherapy with immune checkpoint inhibitors (ICIs) has become a well-established modality to treat a number of different malignancies, especially in cases with advanced stages and/or recurrent diseases. These agents have been associated with development of a...

Cite
Crout TM, Lennep DS, Kishore S, et al. Systemic Vasculitis Associated With Immune Check Point Inhibition: Analysis and Review. Curr Rheumatol Rep. 2019;21(6):28doi: 10.1007/s11926-019-0828-7.
Crout, T. M., Lennep, D. S., Kishore, S., & Majithia, V. (2019). Systemic Vasculitis Associated With Immune Check Point Inhibition: Analysis and Review. Current rheumatology reports, 21(6), 28. https://doi.org/10.1007/s11926-019-0828-7
Crout, Teresa M, et al. "Systemic Vasculitis Associated With Immune Check Point Inhibition: Analysis and Review." Current rheumatology reports vol. 21,6 (2019): 28. doi: https://doi.org/10.1007/s11926-019-0828-7
Crout TM, Lennep DS, Kishore S, Majithia V. Systemic Vasculitis Associated With Immune Check Point Inhibition: Analysis and Review. Curr Rheumatol Rep. 2019 May 21;21(6):28. doi: 10.1007/s11926-019-0828-7. PMID: 31115712.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 14 entries